ABAnastasios Bonakis

Anastasios Bonakis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anastasios Bonakis has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Brivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence

    by Anna Keramida, Katerina Poprelka, Meropi Mousdi, Vasiliki Kotsali-Peteinelli, Maria-Ioanna Stefanou, Anastasios Bonakis, Georgios Tsivgoulis, Andreas Kyrozis, Panagiota-Eleni Tsalouchidou

    Background: Brivaracetam (BRV) is a synaptic vesicle protein 2A (SV2A) ligand approved for the treatment of focal-onset seizures. Its clinical use has increasingly expanded beyond approved indications and into understudied populations. Objective: We aim to review BRV use beyond approved indications and in special populations. Methods: MEDLINE, Embase, and Scopus were searched from inception to 30 April 2026. Eligible clinical studies were selected using prespecified criteria and synthesized narratively. Off-label status was determined separately under FDA and EMA labelling. Results: The evidence consisted predominantly of observational studies, real-world cohorts, case series, and subgroup analyses of randomised trials. In genetic generalized epilepsies (GGE), BRV was associated with seizure reduction in several cohorts, whereas findings in developmental and epileptic encephalopathies (DEEs) were more heterogeneous. Real-world studies demonstrated the feasibility of BRV monotherapy, particularly following transition from levetiracetam. In status epilepticus (SE), intravenous BRV has been associated with SE cessation, although its independent contribution, optimal dose and timing, and role in treatment algorithms remain uncertain. Pregnancy and breastfeeding reports identified no clear safety signal, although exposure and long-term outcome data were scarce. Neonatal evidence was restricted largely to pharmacokinetic and short-term tolerability findings. Observational data indicated that psychiatric or behavioural adverse effects did not recur in some patients switched from levetiracetam; evidence in psychotic disorders remained particularly limited. Conclusions: BRV may be useful in selected off-label settings and special populations. However, evidence remains limited and largely observational, so treatment decisions should be individualized. Prospective controlled studies and dedicated registries are needed.

  • Open Access

    What shapes health-related quality of life in drug-resistant epilepsy? Clinical, emotional, and cognitive predictors

    by Katerina Poprelka, Panagiota-Eleni Tsalouchidou, Konstantina Stavrogianni, Maria Stefanatou, Anastasia Verentzioti, Anna Keramida, Vasiliki Kotsali-Peteinelli, Athanasia Alexoudi, Anastasios Bonakis, Stylianos Gatzonis

  • Open Access

    Psychological resilience as a key pathway between depression and executive functioning in epilepsy

    by Katerina Poprelka, Panagiota-Eleni Tsalouchidou, Konstantina Stavrogianni, Maria Stefanatou, Anastasia Verentzioti, Anna Keramida, Vasiliki Kotsali-Peteinelli, Athanasia Alexoudi, Anastasios Bonakis, Lampis C. Stavrinou, et al.

  • Open Access

    Resilience as a mediating mechanism between psychological distress and quality of life in epilepsy

    by Katerina Poprelka, Konstantina Stavrogianni, Panagiota-Eleni Tsalouchidou, Maria Stefanatou, Anna Keramida, Anastasia Verentzioti, Vasiliki Kotsali-Peteinelli, Athanasia Alexoudi, Anastasios Bonakis, Lampis C. Stavrinou, et al.

  • Open Access

    Neuroimaging of the ictal–interictal continuum: Where do we stand? A systematic review and meta‐analysis of current evidence

    by Panagiota‐Eleni Tsalouchidou, Kateriine Orav, Tiago Lerda‐Casaccia, Leona Möller, Georgios Tsivgoulis, Anastasios Bonakis, Lukas Machegger, Giorgi Kuchukhidze, Susanne Knake, Eugen Trinka, et al.

    Objective: Patterns within the ictal–interictal continuum (IIC) are frequently encountered in critically ill patients undergoing continuous electroencephalographic studies and may reflect ongoing ictal activity or secondary brain injury. Peri‐ictal neuroimaging abnormalities (PNA) have been described in association with status epilepticus (SE), but their occurrence in patients with IIC across different neuroimaging modalities remains incompletely characterized. We aimed to assess the occurrence of PNA in adults with IIC across structural and functional neuroimaging techniques. Methods: We performed a systematic review and meta‐analysis following PRISMA 2020 guidelines. PubMed, Embase, and Scopus were searched up to January 2026 for studies reporting PNA in adults with IIC. Eligible modalities included magnetic resonance imaging (MRI), CT perfusion (CTP), and positron emission tomography (PET). Pooled detection rates were estimated using random‐effects generalized linear mixed models. Results: Of 8400 records identified, seven studies met the inclusion criteria. Of these, four contributed MRI data (98 patients), two—CTP data (38 patients), and two—PET data (30 patients); no SPECT study was identified. One study contributed data to two modalities. Pooled proportion of PNA was 0.41 (95% CI: 0.30–0.52; I 2 = 30.4%) for MRI, 0.34 (95% CI: 0.21–0.50; I 2 = 0%) for CTP, and 0.90 (95% CI: 0.73–0.97; I 2 = 0%) for PET. Significance: There are currently a limited number of studies evaluating PNA in IIC. PET showed the highest pooled proportion of PNA, although these findings should be interpreted cautiously. Further studies are required to better define the neuroimaging spectrum within the IIC and to clarify its clinical and diagnostic implications.

  • Alexithymia and its relationship with cognition and psychological outcomes in patients with drug-resistant epilepsy

    by Katerina Poprelka, Panagiota-Eleni Tsalouchidou, Konstantina Stavrogianni, Anna Keramida, Vasiliki Kotsali-Peteinelli, Maria Stefanatou, Anastasia Verentzioti, Athanasia Alexoudi, Anastasios Bonakis, Stylianos Gatzonis

  • Open Access

    The Biomarker Profile of Alzheimer’s Disease for Disease-Modifying Treatment Eligibility: Questions and Debates

    by Athanasia Athanasaki, Ioanna Tsantzali, Aikaterini Theodorou, Amalia Michalopoulou, Vasilios C. Constantinides, Fotini Boufidou, John S. Tzartos, Panagiota-Eleni Tsalouchidou, Christina Zompola, Sotirios G. Paraskevas, et al.

    Alzheimer’s disease (AD) is the most common cause of cognitive decline; currently, anti-amyloid monoclonal antibodies are available for clinical use as disease-modifying treatments, while many other substances are being tested in clinical trials. Molecular biomarkers for AD have been studied for more than two decades, and various guidelines and diagnostic recommendations have been published. However, there are still questions and controversies about the biomarker profile needed to confirm AD and the eligibility for such established treatments and clinical trials. Is amyloid positivity sufficient for eligibility, or is a biomarker for tau biochemistry/pathology also needed? What is the role of hybrid ratios combining amyloid and tau? Should we rely on plasma biomarkers alone? This review aimed to describe and discuss such questions and controversies.


  • Open Access

    APOE Genotyping in Cognitive Disorders: Preliminary Observations from the Greek Population

    by Athanasia Athanasaki, Ioanna Tsantzali, Christos Kroupis, Aikaterini Theodorou, Fotini Boufidou, Vasilios C. Constantinides, John S. Tzartos, Socrates J. Tzartos, Georgios Velonakis, Christina Zompola, et al.

    Alzheimer’s disease (AD) is the most common cause of cognitive decline. Among the various susceptibility genes, the gene of apolipoprotein E (APOE) is probably the most important. It may be present in three allelic forms, termed ε2, ε3 and ε4, and the most common genotype is the ε3/ε3. Recently, it has been observed that subjects with the ε4/ε4 genotype may show near-full penetrance of AD biology (pathology and biomarkers), leading to the suggestion that ε4 homozygosity may represent a distinct genetic type of AD. The aim of the present study was to investigate the role of ε4 homozygosity or heterozygosity in the presence or absence of the AD biomarker profile in patients with cognitive disorders in the Greek population. A total of 274 patients were included in the study. They underwent APOE genotyping and cerebrospinal fluid (CSF) biomarker profiling. The presence of ε4 was associated with a lower age of symptom onset and decreased amyloid biomarkers (irrespective to AD or non-AD profiles), and predicted the presence of an AD profile by a positive predictive value approaching 100%. In conclusion, the ε4 allele has a significant effect on the risk and clinical parameters of cognitive impairment and AD in the Greek population, while the ε4/ε4 genotype may be highly indicative of the (co)existence of AD in cognitively impaired patients.


  • Open Access

    Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: A case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence

    by Zafeirenia Vlakou, Anna Keramida, Vasiliki Kotsali-Peteinelli, Alexandros Matsingos, Maria Konstantinidi, Maria Chondrogianni, Georgios Tsivgoulis, Anastasios Bonakis, Panagiota-Eleni Tsalouchidou


  • Open Access

    Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A+T+ (A+T1+) Alzheimer’s Disease

    by Ioanna Tsantzali, Athanasia Athanasaki, Fotini Boufidou, Vasilios C. Constantinides, Maria-Ioanna Stefanou, Christos Moschovos, Christina Zompola, Sotirios G. Paraskevas, Anastasios Bonakis, Sotirios Giannopoulos, et al.

    Background: Alzheimer’s disease (AD) may present with pure (typical or atypical) and mixed phenotypes, sometimes causing difficulties in (differential) diagnosis. In order to achieve a diagnostic accuracy as high as possible, the diagnosis of AD during life depends on various biomarkers, including the cerebrospinal fluid (CSF) biomarkers. Methods: Classical CSF AD biomarkers were determined in a total of 61 patients, classified as both beta amyloid- and tau-positive A+T+ (or A+T1+ according to the recently revised Alzheimer Association criteria for diagnosis and staging of AD). Twenty one of these patients fulfilled the criteria for mixed AD (mixed with Lewy bodies, cerebrovascular disease, or normal pressure hydrocephalus), whilst 40 had pure AD. Results: Patients did not differ with respect to gender, education, disease duration, and cognitive status. After controlling for confounding factors, no difference was observed between mixed and pure AD groups in Aβ42 or Aβ42/Aβ40 levels. Although by definition, patients of both groups had abnormal (increased) levels of phospho-tau181, the mixed AD group presented with lower (less abnormal) levels of phospho-tau181 and total tau as compared to the pure group. Conclusions: In patients with AD of comparable cognitive status, mixed AD cases may present with lower levels of tau proteins and, if close to the cut-off values, diagnostic uncertainty may be increased.